- Home
- ANAB vs IGIC Comparison
ANAB vs IGIC Comparison
Compare ANAB & IGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- IGIC
- Stock Information
- Founded
- ANAB 2005
- IGIC 2001
- Country
- ANAB United States
- IGIC Jordan
- Employees
- ANAB N/A
- IGIC N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- IGIC Property-Casualty Insurers
- Sector
- ANAB Health Care
- IGIC Finance
- Exchange
- ANAB Nasdaq
- IGIC Nasdaq
- Market Cap
- ANAB 1.0B
- IGIC 1.0B
- IPO Year
- ANAB 2017
- IGIC N/A
- Fundamental
- Price
- ANAB $42.39
- IGIC $24.09
- Analyst Decision
- ANAB Buy
- IGIC Buy
- Analyst Count
- ANAB 12
- IGIC 2
- Target Price
- ANAB $63.80
- IGIC $31.50
- AVG Volume (30 Days)
- ANAB 735.4K
- IGIC 104.1K
- Earning Date
- ANAB 11-04-2025
- IGIC 11-04-2025
- Dividend Yield
- ANAB N/A
- IGIC 4.36%
- EPS Growth
- ANAB N/A
- IGIC N/A
- EPS
- ANAB N/A
- IGIC 2.81
- Revenue
- ANAB $169,467,000.00
- IGIC $525,808,999.00
- Revenue This Year
- ANAB $37.52
- IGIC $6.05
- Revenue Next Year
- ANAB N/A
- IGIC $7.01
- P/E Ratio
- ANAB N/A
- IGIC $8.56
- Revenue Growth
- ANAB 196.42
- IGIC 3.88
- 52 Week Low
- ANAB $12.21
- IGIC $20.82
- 52 Week High
- ANAB $43.31
- IGIC $27.76
- Technical
- Relative Strength Index (RSI)
- ANAB 71.33
- IGIC 67.37
- Support Level
- ANAB $33.10
- IGIC $23.31
- Resistance Level
- ANAB $43.31
- IGIC $24.26
- Average True Range (ATR)
- ANAB 2.88
- IGIC 0.53
- MACD
- ANAB 0.51
- IGIC 0.15
- Stochastic Oscillator
- ANAB 91.49
- IGIC 94.37
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About IGIC International General Insurance Holdings Ltd.
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.